Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Shares Issued (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Shares Issued for 9 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 103.59% to $8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.5 million, a 51.35% decrease, with the full-year FY2025 number at $8.5 million, down 51.35% from a year prior.
  • Shares Issued was $8.5 million for Q4 2025 at Denali Therapeutics, up from $4.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $499.3 million in Q1 2024 to a low of -$491.5 million in Q2 2024.
  • A 5-year average of $3.7 million and a median of $4.4 million in 2022 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 31025.5% in 2024; the steepest drop was 30540.59% in 2024.
  • Denali Therapeutics' Shares Issued stood at $5.2 million in 2021, then plummeted by 313.22% to -$11.0 million in 2022, then skyrocketed by 142.7% to $4.7 million in 2023, then fell by 11.69% to $4.2 million in 2024, then surged by 103.59% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Shares Issued are $8.5 million (Q4 2025), $4.2 million (Q4 2024), and $5.5 million (Q3 2024).